Logo image
IRO Home Research units Researcher Profiles
Sign in
Genetic Testing to Guide Warfarin Dosing: Impact of Direct Oral Anticoagulants
Journal article   Peer reviewed

Genetic Testing to Guide Warfarin Dosing: Impact of Direct Oral Anticoagulants

S. R. Lentz
Clinical pharmacology and therapeutics, Vol.100(2), pp.128-130
08/01/2016
DOI: 10.1002/cpt.395
PMID: 27178490

View Online

Abstract

Despite rapid growth in the use of direct oral anticoagulants (DOACs), warfarin remains a widely prescribed anticoagulant drug. It is likely that the overall use of warfarin will continue to decline, but not completely disappear, as indications for DOACs expand. This changing anticoagulation landscape, along with the likelihood that personalized genomic information will become increasingly available, has several implications for the future of warfarin dosing strategies.
Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology

Details

Metrics

Logo image